Laurus Labs and Nucelion Therapeutics announce strategic expansions

Laurus Labs has entered into agreements to acquire stakes in two companies to bolster its manufacturing capabilities. The company will acquire a 60 per cent stake in Canada-based Galenvs Science for USD 3.75 million and a 52 per cent stake in Hyderabad-based SI&C Resins for Rs 32 crore. The Galenvs Science acquisition aims to expand Laurus Labs' presence in custom oligonucleotide synthesis and functional magnetic nanoparticle technologies, providing access to an R&D pipeline for the North American market.

In a separate development, Nucelion Therapeutics, a subsidiary of Bharat Biotech, has partnered with Pandorum Technologies to advance two investigational therapies for eye diseases. The collaboration focuses on advanced keratopathy and wet age-related macular degeneration. Nucelion will provide process development and manufacturing support for Pandorum’s designer exosome-based regenerative medicines, aiming to produce materials under Good Manufacturing Practice standards for clinical studies in India and international markets.